Evotec AG (NASDAQ:EVTCY) has earned an average broker rating score of 2.00 (Buy) from the two brokers that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a hold rating and one has issued a strong buy rating on the company. Evotec AG’s rating score has improved by 33.3% from three months ago as a result of a number of analysts’ ratings changes.

Zacks has also given Evotec AG an industry rank of 162 out of 265 based on the ratings given to its competitors.

Several brokerages have commented on EVTCY. Zacks Investment Research downgraded shares of Evotec AG from a “buy” rating to a “hold” rating in a report on Tuesday. DZ Bank AG restated a “sell” rating on shares of Evotec AG in a report on Thursday, August 17th.

Evotec AG (NASDAQ EVTCY) traded up 0.42% on Wednesday, hitting $47.90. 208 shares of the stock traded hands. The stock has a market capitalization of $3.53 billion and a P/E ratio of 80.37. The company’s 50 day moving average price is $43.88 and its 200-day moving average price is $31.79. Evotec AG has a 12-month low of $10.82 and a 12-month high of $52.82.

Evotec AG (NASDAQ:EVTCY) last announced its earnings results on Thursday, August 10th. The company reported $0.04 EPS for the quarter, missing the consensus estimate of $0.07 by ($0.03). The business had revenue of $58.52 million for the quarter, compared to analysts’ expectations of $50.06 million.

ILLEGAL ACTIVITY WARNING: “Zacks: Evotec AG (EVTCY) Receives Average Rating of “Buy” from Brokerages” was first posted by American Banking News and is owned by of American Banking News. If you are reading this story on another publication, it was copied illegally and reposted in violation of international trademark & copyright law. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/10/11/zacks-evotec-ag-evtcy-receives-average-rating-of-buy-from-brokerages.html.

Evotec AG Company Profile

Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners’ target through a range of commercial structures, including research fees, milestones and/or royalties.

Get a free copy of the Zacks research report on Evotec AG (EVTCY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Evotec AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec AG and related companies with MarketBeat.com's FREE daily email newsletter.